Table A3.
Main features of the questionnaire findings for the oncology indication.
| Interest for the Device | Oncology Only (n = 24) | Both (n = 55) | p-Value |
|---|---|---|---|
| Usage of the Device | 0.24 | ||
| User | 10 (41.7%) | 29 (53.7%) | |
| Prescriber | 2 (8.3%) | 9 (16.7%) | |
| Both | 12 (50.0%) | 16 (29.6%) | |
| Number of Patients with Metastatic Pre-Fractural Lesions at the Proximal Hip, per Month | 1.00 | ||
| <5 | 23 (95.8%) | 50 (92.6%) | |
| 5–12 | 1 (4.2%) | 4 (7.4%) | |
| Medical Treatment for Osteolytic Metastasis at the Proximal Femur | 0.75 | ||
| YES | 15 (75.0%) | 26 (78.8%) | |
| NO | 5 (25.0%) | 7 (21.2%) | |
| Main Medical Treatment Prescribed | 0.17 | ||
| Chemotherapy | 1 (7.1%) | 4 (15.4%) | |
| Local Radiotherapy | 1 (7.1%) | 8 (30.8%) | |
| Chemotherapy + Local Radiotherapy | 12 (85.7%) | 13 (50.0%) | |
| Other | 0 (0%) | 1 (3.8%) | |
| Main type of Primary Cancer Associated to Osteolytic Metastasis at the Proximal Femur* | |||
| Lung | 18 (75.0%) | 28 (50.9%) | 0.052 |
| Breast | 17 (70.8%) | 42 (76.4%) | 0.59 |
| Prostate | 10 (41.7%) | 24 (43.6%) | 1.00 |
| Kidney | 11 (45.8%) | 18 (32.7%) | 0.31 |
| Melanoma | 3 (12.5%) | 1 (1.8%) | 0.081 |
| Other | 1 (4.2%) | 2 (3.6%) | 1.00 |
| Preventive Treatment for Proximal Femur Fracture Proposed to Patients | 0.74 | ||
| Mainly NO | 9 (39.1%) | 20 (37.0%) | |
| Mainly YES | 14 (60.9%) | 34 (63%) | |
| Main Preventive Treatment Proposed for Proximal Femur Fracture | 0.70 | ||
| Osteosynthesis in Orthopaedics Theatre | 11 (47.8%) | 35 (63.6%) | |
| Screwing + Cementoplasty | 4 (17.4%) | 7 (12.7%) | |
| Cementoplasty Alone | 1 (4.35%) | 2 (3.6%) | |
| No Prevention | 6 (26.1%) | 9 (16.4%) | |
| Other | 1 (4.35%) | 2 (3.6%) | |
| Main Criteria of Choice for Preventive Treatment* | |||
| Size of the Lesion | 17 (70.8%) | 41 (74.5%) | 0.78 |
| Pain | 11 (45.8%) | 26 (47.3%) | 1.00 |
| Easy-to-Use | 7 (29.2%) | 17 (30.9%) | 1.00 |
| Material Availability | 3 (12.5%) | 8 (14.5%) | 1.00 |
| Cost | 2 (8.3%) | 4 (7.3%) | 1.00 |
| Anaesthesia Choice for Preventive Treatment | 0.59 | ||
| Mostly General | 13 (72.2%) | 31 (64.6%) | |
| Mostly Spinal | 4 (22.2%) | 11 (22.9%) | |
| Both Similarly | 1 (5.6%) | 5 (10.4%) | |
| Other | 0 (0%) | 1 (2.0%) | |
| Mean Surgical Time for Hip Fracture Treatment, min | 0.66 | ||
| <30 | 5 (29.4%) | 10 (22.2%) | |
| 30–60 | 9 (52.9%) | 29 (64.4%) | |
| >60 | 3 (17.7%) | 6 (13.3%) | |
| Willing to Use/Prescribe Y-STRUT® in Prevention | 1.00 | ||
| YES | 15 (93.7%) | 40 (93.0%) | |
| NO | 1 (6.3%) | 3 (7.0%) | |
| Questionnaire Satisfaction, median [Q1;Q3] | 72.5 [66.25;88.5] | 72 [54.25;90] | 0.77 |
| 100: very satisfied, 0: not satisfied at all | (n = 24) | (n = 54) |